OR WAIT 15 SECS
Margaret M. Faul is vice-president, Drug Product Technologies, Process Development, Amgen.
Carl L. McMillian is vice-president, Toxicology, Drug Disposition, PK/PD, Eli Lilly and Company.
Pierre Boulas is executive director, Product and Technology Development, Biogen.
Reginaldo A. Saraceno is director, Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals.
Mary Devlin Capizzi is partner, Faegre Drinker Biddle & Reath LLP.
Maureen T. Cruz is senior manager, Science, Regulation and Policy, Faegre Drinker Biddle & Reath LLP.
The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.
Pharmaceutical development is a long, risky, and expensive process. In this highly competitive market, pharmaceutical companies are under constant pressure to deliver innovation via new therapeutics, new technology, and improved efficiency and effectiveness (1). Precompetitive collaboration is recognized as a mechanism to enhance efficiency, mitigate risks, and share costs that can benefit industry, academia, and government agencies. For the purposes of this viewpoint, “precompetitive collaboration” may be defined as collaborations between pharmaceutical companies and third parties to produce an efficiency-enhancing advancement or refinement that will be made broadly available to the public (i.e., publication, commercialization of a new product).
eBook: Regulatory Sourcebook, October 2020
When referring to this article, please cite it as M. M. Faul et al.,“Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation," BioPharm International Regulatory Sourcebook eBook (October 2020).